Mara Goldstein
Former Managing Director, Biotechnology Analyst
Mizuho Securities
Mara Goldstein was most recently a senior biotechnology and managing director with Mizuho Securities, providing research coverage of oncology-focused companies. Ms Goldstein joined Mizuho Securities in late 2018, following her tenure with Cantor Fitzgerald that spanned seven years, where she served as a senior biotechnology analyst and head of the healthcare group, and in a dual capacity as research analyst and director of research beginning in 2016. During her time with Cantor, healthcare coverage grew to over 130 stocks spanning multiple sub-sectors, and helped to launch Cantor’s healthcare conference program. Prior to Cantor Fitzgerald, Ms Goldstein headed the healthcare team at Reuters Insight (Anian), and later head of the research group. Ms Goldstein also spent eight years with CIBC World Markets (now Oppenheimer) as an executive director and senior analyst covering large capitalization pharmaceutical companies, drug delivery companies and contract research organizations (CROs). Before joining CIBC World Markets, Ms Goldstein was an associate analyst with Alex. Brown & Sons (now Deutsche Bank), covering biotechnology, drug delivery, large cap pharmaceuticals, PBMs and drug distribution companies. Ms Goldstein has been quoted in numerous national publications such as The Wall Street Journal, The New York Times, The Financial Times, as well as news sources such as Bloomberg, Thomson Reuters, and has been a guest on CNBC and ABC’s World News Tonight.
Ms Goldstein graduated from Purdue University with a Bachelor of Science in economics and minors in history and French. Ms Goldstein currently holds FINRA Series 7, 63, 86, 87, 24 and SIE licenses.